RxDoctor Payments Data

Peterkin Lee Kwen, MD

Neurology · West Seneca, NYNPI 1811966880

Payments from drug & device makers

$27,273in general payments, 2019–2025

Across 1,281 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Biogen$2K
  • AbbVie$2K
  • Pfizer$1K
  • UCB, Inc.$1K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$1,9207%
  • Food & beverage$24,68190%
  • Education$6722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amneal Pharmaceuticals LLC30$2,055
Teva Pharmaceuticals USA, Inc.64$1,831
Biogen81$1,665
AbbVie(2 entities)80$1,518
Pfizer76$1,367
UCB, Inc.80$1,322
Novartis61$1,038
EMD Serono, Inc.55$981
SK Life Science, Inc.39$943
Argenx US, Inc.18$661
Amgen34$636
Sanofi31$634
TG Therapeutics, Inc.22$583
AstraZeneca(2 entities)24$571
Genentech USA, Inc.29$551
Eisai Inc.27$528
Neurocrine Biosciences, Inc.31$514
Johnson & Johnson(2 entities)24$498
Lundbeck LLC23$484
Bristol Myers Squibb23$436
Merz Pharmaceuticals, LLC13$413
Supernus Pharmaceuticals, Inc.20$370
Upsher-smith Laboratories LLC19$345
Catalyst Pharmaceuticals, Inc.16$335
Grifols USA, LLC14$328
Acadia Pharmaceuticals Inc18$323
Neurelis, Inc.15$322
CSL Behring16$314
Vanda Pharmaceuticals Inc.14$310
MDD US Operations, LLC17$309
Sunovion Pharmaceuticals Inc.13$308
Biohaven Pharmaceuticals, Inc.23$300
Lilly USA, LLC16$282
Biohaven Pharmaceutical Holding Company Ltd.17$256
Merz North America, Inc.9$254
Mallinckrodt Hospital Products Inc.13$250
Livanova USA, Inc.12$208
Abbott7$197
Otsuka America Pharmaceutical, Inc.9$171
E.r. Squibb & Sons, L.L.C.9$164
Kyowa Kirin, Inc.8$147
Mallinckrodt Enterprises LLC5$140
Axsome Therapeutics, Inc.6$138
Adamas Pharmaceuticals, Inc.8$126
Jazz Pharmaceuticals Inc.5$120
Tanabe Pharma America, Inc.6$113
Azurity Pharmaceuticals, Inc.1$108
Acorda Therapeutics, Inc6$103
Baxter Healthcare1$99
Promius Pharma LLC5$97
ANI Pharmaceuticals, Inc.5$91
Takeda Pharmaceuticals U.S.A., Inc.4$89
Cycle Pharmaceuticals Inc4$86
Impel Pharmaceuticals Inc.5$83
Banner Life Sciences, LLC5$76
Tonix Medicines, Inc.5$76
Sanofi-aventis U.S. LLC4$75
Harmony Biosciences LLC3$68
Currax Pharmaceuticals LLC4$66
Boston Scientific3$63

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,273 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$326,932
Medicare patients
478
Services billed
18,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 46101$757,600
Kesimpta PenOfatumumab61$586,885
OctagamImmun Globg(Igg)/Malt/Iga Ov5030$519,258
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5043$434,617
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5021$228,617
TysabriNatalizumab26$215,175
GammakedImmune Globul G/Gly/Iga Avg 4617$133,274
Teriflunomide42$132,720
Austedo XrDeutetrabenazine21$116,555
XcopriCenobamate99$115,870
AptiomEslicarbazepine Acetate68$105,244
VumerityDiroximel Fumarate12$103,021
FycompaPerampanel92$102,209
IngrezzaValbenazine Tosylate12$100,111
AustedoDeutetrabenazine16$92,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$328$757,600101 claims
PfizerOctagam, Nurtec Odt, Eliquis, Dilantin$1,367$596,126134 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$89$434,61743 claims
BiogenTysabri, Vumerity$1,665$318,19638 claims
CSL BehringPrivigen$314$228,61721 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$1,831$209,25837 claims
SK Life Science, Inc.Xcopri$943$115,87099 claims
Sunovion Pharmaceuticals Inc.Aptiom$308$105,24468 claims
Eisai Inc.Fycompa$528$102,20992 claims
Neurocrine Biosciences, Inc.Ingrezza$514$100,11112 claims
UCB, Inc.Briviact$1,322$71,26849 claims
Acadia Pharmaceuticals IncNuplazid$323$49,37611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in West Seneca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →